Meta-Analysis of the Placebo Response in Chronic and Episodic Migraine: Insights from Migraine Preventive Drug Trials
Abstract
Randomized, well-controlled trials are the gold-standard for evaluating novel therapies, but they often fail to fully account for the placebo response, particularly in pain-related conditions such as migraine, where subjective improvement is common in placebo groups. This placebo response is influenced by individual-level factors, such as prior treatment experience, expectations of treatment benefit, and demographic characteristics such as age, race, sex, and clinical trial location. As clinical trials grow increasingly global and diverse, ensuring balanced demographic distribution across treatment arms is essential to accurately assess efficacy. We conducted a meta-analysis of placebo arm data from 14 pivotal Phase 2 and 3 trials that supported approval of six drugs for the preventive treatment of episodic and chronic migraine. Data were stratified by migraine type and analyzed by demographic variables including age, sex, race, menopause status, trial region, prior prophylactic medication use, route of administration, and frequency. Changes from baseline were evaluated for monthly migraine days (primary endpoint) and migraine-related symptoms (e.g., headache days, headache days of moderate/severe intensity, photophobia/phonophobia days, and nausea/vomiting days). Placebo responses were consistently higher in subjects who had not used prior preventive medications, African Americans, and participants enrolled in North America. These findings suggest that placebo response in…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.